TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Intravenous Nutrition Development, Research Organization (INDRO) AB
Closing information (x1000 DKK)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
202
|
158
|
120 |
Financial expenses |
0
|
2
|
0 |
Earnings before taxes |
286
|
1
![]() |
1 |
EBITDA |
-84
|
2
|
1 |
Total assets |
3,394
|
3,036
|
3,268 |
Current assets |
414
|
71
|
41 |
Current liabilities |
140
|
83
|
55 |
Equity capital |
3,254
|
2,953
|
3,212 |
- share capital |
134
![]() |
134
|
145 |
Employees (average) |
1
![]() |
1
![]() |
1 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
95.9%
|
97.3%
|
98.3% |
Turnover per employee |
202
|
158
|
120 |
Profit as a percentage of turnover |
141.6%
|
0.6%
|
0.8% |
Return on assets (ROA) |
8.4%
|
0.1%
|
0.0% |
Current ratio |
295.7%
|
85.5%
|
74.5% |
Return on equity (ROE) |
8.8%
|
0.0%
![]() |
0.0% |
Change turnover |
42
|
48
|
31 |
Change turnover % |
27%
|
44%
|
35% |
Chg. No. of employees |
0
![]() |
0
![]() |
0 |
Chg. No. of employees % |
0%
![]() |
0%
![]() |
0% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.